Sodium–glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction

by Adamo, M., Anker, S.D, Butler, J., Coats, A.J.S, Filippatos, G., Fonarow, G.C, Greene, S.J, McDonagh, T.A, Metra, M., Ponikowski, P., Rosano, G., Seferovic, P., Tomasoni, D., Vaduganathan, M., Voors, A.A
Published 2022

Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA)...

by Backs, J., Carrier, L., Coats, A.J.S, de Boer, R.A, Dimmeler, S., Eschenhagen, T., Filippatos, G., Gepstein, L., Heymans, S., Hulot, J.-S, Knöll, R., Kupatt, C., Linke, W.A, Seferovic, P.M, Seidman, C.E, Thum, T., Tocchetti, C.G, van der Velden, J., Walsh, R.
Published 2022